HeyJaredZeel Mehta
- Indexed articles, last 90 days
- 13
- Latest publication
- Sep 22, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 14, 2026
Latest articles
EMA Supports Pediatric Expansion of Relapsing MS Therapy (opens the original)
Read excerpt
Children aged 10 years or older with relapsing forms of multiple sclerosis (RMS) could soon gain access in Europe to Ocrevus (ocrelizumab, Roche Registration GmbH). The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended extending the drug’s marketing authorization to include pediatric patients aged 10 years or older with RMS with active disease defined by clinical or imaging features. Ocrevus is already approved in the European Union for adu
SMC Backs Gene Therapy for Metachromatic Leukodystrophy (opens the original)
Read excerpt
The Scottish Medicines Consortium (SMC) has accepted atidarsagene autotemcel (Libmeldy, Orchard Therapeutics Limited) for routine use within NHS Scotland to treat metachromatic leukodystrophy (MLD) in children with biallelic ARSA mutations, after reassessment under the ultra-orphan pathway. The gene therapy had previously been available while further evidence on its effectiveness was collected. It is indicated for presymptomatic children with late-infantile or early juvenile MLD, and for those w
EMA Probes Injectable Iron Medicines for Bone Risks (opens the original)
Read excerpt
Reports of severe hypophosphatemia linked to injectable iron medicines — including cases of osteomalacia after just one or two doses and in patients with no recognized risk factors — have prompted a European safety review. The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has launched the review across all injectable iron formulations, not only ferric carboxymaltose, amid concerns that current risk-minimization measures may not be sufficient. Injectable iron is u
NICE Supports Weekly Insulin Jab for Type 2 Diabetes (opens the original)
Read excerpt
The National Institute for Health and Care Excellence (NICE) has recommended once-weekly insulin efsitora alfa (Onswik, Eli Lilly) as a new treatment option for adults with type 2 diabetes, subject to marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA). In final draft guidance, NICE said the once-weekly injection could cut the number of annual insulin injections from 365 to 52 for people switching from a daily basal insulin regimen — an 85% reduction. Insu
SMC OKs First C5 Inhibitor for Refractory Myasthenia Gravis (opens the original)
Read excerpt
The Scottish Medicines Consortium (SMC) has accepted zilucoplan (Zilbrysq, UCB Pharma Ltd) for restricted use in NHS Scotland as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. The recommendation applies to patients with refractory gMG who have not responded adequately to corticosteroids and at least two other treatments, including non-steroidal immunosuppressive therapies and r
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.